209 related articles for article (PubMed ID: 19787093)
1. Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.
Tamamura H; Tsutsumi H; Nomura W; Fujii N
Perspect Medicin Chem; 2008 Feb; 2():1-9. PubMed ID: 19787093
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
3. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
4. A future perspective on the development of chemokine receptor CXCR4 antagonists.
Tamamura H; Tsutsumi H; Nomura W; Tanaka T; Fujii N
Expert Opin Drug Discov; 2008 Oct; 3(10):1155-66. PubMed ID: 23489074
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Fujii N
Expert Opin Ther Targets; 2005 Dec; 9(6):1267-82. PubMed ID: 16300475
[TBL] [Abstract][Full Text] [Related]
8. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.
Liekens S; Schols D; Hatse S
Curr Pharm Des; 2010; 16(35):3903-20. PubMed ID: 21158728
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4.
Kofuku Y; Yoshiura C; Ueda T; Terasawa H; Hirai T; Tominaga S; Hirose M; Maeda Y; Takahashi H; Terashima Y; Matsushima K; Shimada I
J Biol Chem; 2009 Dec; 284(50):35240-50. PubMed ID: 19837984
[TBL] [Abstract][Full Text] [Related]
10. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
11. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
12. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
13. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
14. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
15. The chemokine receptor CXCR4 as a therapeutic target for several diseases.
Tamamura H; Tsutsumi H; Fujii N
Mini Rev Med Chem; 2006 Sep; 6(9):989-95. PubMed ID: 17017998
[TBL] [Abstract][Full Text] [Related]
16. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
17. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
Peng D; Cao B; Zhou YJ; Long YQ
Eur J Med Chem; 2018 Apr; 149():148-169. PubMed ID: 29500940
[TBL] [Abstract][Full Text] [Related]
18. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
19. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.
Boulais PE; Dulude D; Cabana J; Heveker N; Escher E; Lavigne P; Leduc R
Biochem Pharmacol; 2009 Dec; 78(11):1382-90. PubMed ID: 19631193
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]